TXMD · TherapeuticsMD, Inc. · Financials
$2.16
+0.06 (+2.86%)
At close · Sep 11
View the 10-Q filed Aug 11, 2026
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed Aug 11, 2026
Customer concentration
— top 3 customers 100% of revenue
3 customers — 100% of revenue (the three and six months ended June 30, 2026)
“For the three and six months ended June 30, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Market Cap
$25.00M
Shares
11.57M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$3.02M
+71.6%
FY2025
Net Income
-$569K
+73.9%
FY2025
Gross Margin
100%
+2pp
FY2023
Operating Margin
-145.27%
+201.8pp
FY2025
Diluted EPS
-$0.05
+73.7%
FY2025
Operating Cash Flow
$2.45M
+109.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.27M | $3.02M | $1.76M | $1.3M | $69.96M | $2.57M | $64.87M | $49.65M | $16.1M | $16.78M | $19.36M | $20.14M | $15.03M | $8.78M | $3.82M | $2.09M | — | |
| — | — | — | — | $1.4M | $1.4M | $15.98M | $6.34M | $2.74M | $2.64M | $4.19M | $4.51M | $3.67M | $1.96M | $1.35M | $947.11K | — | |
| — | — | — | $1.3M | $68.57M | $1.17M | $48.9M | $43.31M | $13.36M | $14.14M | $15.17M | $15.64M | $11.35M | $6.82M | $2.47M | $1.14M | — | |
| — | — | — | 100% | 98% | 45.51% | 75.37% | 87.24% | 83% | 84.28% | 78.38% | 77.63% | 75.56% | 77.67% | 64.69% | 54.64% | — | |
| $5.51M | — | — | — | — | $7.09M | $10.43M | $19.79M | $27.3M | $33.85M | $53.94M | $72.04M | $43.22M | $13.55M | $4.49M | $107.24K | — | |
| $83.71M | — | — | — | — | $108.2M | $117.05M | $114.23M | — | — | — | — | — | — | — | — | — | |
| $6.74M | $6.85M | $6.1M | $8.9M | $56.71M | $80.75M | $76.95M | $60.49M | — | — | — | — | — | — | — | — | — | |
| — | — | $4.74M | $8.9M | — | — | $192.96M | $174.11M | $115.99M | $57.7M | $51.35M | $28.72M | $22.12M | $19.01M | $14.07M | $6.41M | — | |
| — | $176K | $1.27M | $483.5K | — | — | $269.55K | $197.59K | $112.47K | $71.52K | $54.55K | $32.44K | $23.48K | $10.26K | $28.78K | $29.16K | — | |
| $382K | $384K | $509K | $922K | $1.19M | $736K | $4.07M | $1.39M | $293.89K | $213.12K | $132.45K | $62.4K | $52.47K | $58.15K | $56.26K | $54.85K | — | |
| — | — | — | — | $9.47M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $7.22M | $7.41M | $7.87M | $9.83M | $67.38M | $80.75M | $204.44M | $194.52M | $143.58M | $91.77M | $105.42M | $100.83M | $65.4M | $32.62M | $18.62M | $6.57M | — | |
| -$3.95M | -$4.39M | -$6.11M | -$8.52M | $1.19M | -$79.58M | -$155.54M | -$151.21M | -$130.22M | -$77.63M | -$90.25M | -$85.19M | -$54.04M | -$25.81M | -$16.15M | -$5.43M | — | |
| — | -145.27% | -347.08% | -654.61% | 1.7% | -3092.77% | -239.77% | -304.56% | -808.85% | -462.69% | -466.27% | -422.93% | -359.65% | -294.09% | -422.95% | -259.9% | — | |
| -$3.57M | -$4.01M | -$5.6M | -$7.6M | $2.38M | -$78.84M | -$151.47M | -$149.81M | -$129.93M | -$77.42M | -$90.12M | -$85.13M | -$53.99M | -$25.75M | -$16.09M | -$5.37M | — | |
| — | — | — | $300K | $200K | $32.92M | $28.58M | $17.38M | $4.68M | — | — | — | $1.17M | $1.91M | $1.91M | $64.38K | — | |
| — | $142K | $135K | — | — | — | — | — | — | — | $10.82K | $17.44K | $37.31K | $27.23K | — | — | — | |
| $3.69M | $3.74M | $3.77M | $781K | -$117K | $272K | -$27.98M | -$24.94M | -$2.4M | $703.33K | $378.14K | $113.16K | -$176.15K | -$2.61M | -$18.97M | -$7.49M | — | |
| -$263K | -$653K | -$2.34M | -$7.74M | $1.07M | -$79.31M | -$183.52M | -$176.15M | -$132.62M | -$76.93M | -$89.88M | -$85.08M | -$54.22M | -$28.42M | -$35.12M | -$12.91M | — | |
| — | — | -$31K | -$43K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$217K | -$569K | -$2.18M | -$10.28M | $112M | -$172.42M | -$183.52M | -$176.15M | -$132.62M | -$76.93M | -$89.88M | -$85.08M | -$54.22M | -$28.42M | -$35.12M | -$12.91M | -$2.87M | |
| — | -18.83% | -123.85% | -789.4% | 160.08% | -6700.93% | -282.9% | -354.79% | -823.74% | -458.5% | -464.32% | -422.37% | -360.82% | -323.84% | -919.86% | -618.4% | — | |
| — | — | — | -$10.28M | $112M | -$172.42M | -$183.52M | -$176.15M | — | — | — | — | — | — | — | — | — | |
| USD/shares | -$0.02 | -$0.05 | -$0.19 | -$0.99 | $12.41 | -$21.66 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$0.02 | -$0.05 | -$0.19 | -$0.99 | $11.96 | -$21.66 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 11.57M | 11.53M | 10.44K | 9.03M | 7.96M | 5.51M | 4.93M | 4.5M | 4.11M | 3.92M | 3.46M | 2.99M | 2.55M | 1.83M | 1.25M | — |
| shares | — | 11.57M | 11.53M | 10.44K | 9.37M | 7.96M | 5.51M | 4.93M | 4.5M | 4.11M | 3.92M | 3.46M | 2.99M | 2.55M | 1.83M | 1.25M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.00×
EV/EBIT
—
Peer median 8.54×
P/E (TTM)
—
Peer medians compare against the 38 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $1,792,000 | $1,123,000 | $1,003,000 |
| Non Us | $1,230,000 | $638,000 | $299,000 |
By Product & Service (USD)
| Component | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|
| License | $1,302,000 | $69,963,000 | $2,573,000 | $2,000,000 | $15,506,000 | — | — |
| Annovera | — | — | $37,943,000 | $19,611,000 | $6,167,000 | — | — |
| Bijuva | — | — | $10,579,000 | $6,354,000 | $1,836,000 | — | — |
| Imvexxy | — | — | $31,533,000 | $27,139,000 | $16,252,000 | $1,058,201 | — |
| OTC Products | — | — | — | — | — | — | $32,882 |
| Prescription Vitamins | — | — | $5,725,000 | $9,768,000 | $9,886,000 | $15,041,259 | $16,744,831 |
| Theramex | — | — | $2,573,000 | — | — | — | — |